Thane Wettig
Chief Executive Officer bij FIBROGEN, INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
Thane Wettig is currently the Chief Executive Officer & Director at FibroGen, Inc. He previously worked as the Chief Commercial Officer at Intarcia Therapeutics, Inc. and as the Vice President-Diabetes Brands Global Marketing at Lilly Diabetes from 2004 to 2009.
Mr. Wettig completed his undergraduate degree and MBA at Washington University in St. Louis.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
FIBROGEN, INC.
0.48% | 22-03-2024 | 470 396 ( 0.48% ) | 1 M $ | 31-03-2024 |
Actieve functies van Thane Wettig
| Bedrijven | Functie | Begin |
|---|---|---|
| FIBROGEN, INC. | Chief Executive Officer | 23-07-2023 |
Eerdere bekende functies van Thane Wettig
| Bedrijven | Functie | Einde |
|---|---|---|
| Lilly Diabetes | Corporate Officer/Principal | 01-01-2009 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Opleiding van Thane Wettig
| Washington University in St. Louis | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Lilly Diabetes |
